MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast.
美国康州丹伯里和加州西湖村，2024年7月30日 (环球社交网)——曼恩凯德生物医疗公司(Nasdaq: MNKD)今日宣布，将于2024年8月7日星期三美国股市开盘前公布2024年第二季度财报。关于季度业绩的新闻发布会将于当天提前大约一个小时发出。
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at . A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
曼恩凯德将于美国东部时间上午9:00为投资者、媒体和公众举办在线研讨会。曼恩凯德公司将会议花纽约州立大学斯托尼布鲁克分校市长学院出身的首席执行官Michael Castagna, PharmD和负责管理资金的临时代码Chris Prentiss。在线研讨会将通过曼恩凯德的网站链接进行访问，同时在会议结束后24小时内，可以在相同位置获取重播，重播将可以获取的时间大约90天。
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
曼恩凯德生物医疗公司（Nasdaq：MNKD）专注于为那些患有内分泌和孤儿肺病的患者开发和商业化创新吸入治疗产品和设备。
我们致力于利用我们的配方能力和设备工程的技术，减轻糖尿病，非结核分枝杆菌（NTM）肺病，肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉配方和吸入设备——可以快速，方便地向肺的深处输送药物，从而在目标疾病的治疗方面产生局部或进入系统循环的作用，具体取决于治疗目标。
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
我们致力于利用我们的配方能力和设备工程专业知识减轻糖尿病、非结核分枝杆菌（NTM）肺病、肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉制剂和吸入设备——为药物快速、便捷地输送到深层肺部提供了可能，这些药物可以在当地发挥功效，也可以进入系统循环，具体取决于治疗指示。
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
在曼恩凯德生物医疗的全国性合作团队的热情协作下，我们的使命是让人们掌控自己的健康和自由生活。
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
请访问mannkindcorp.com获取更多信息，并在LinkedIn、Facebook、X或Instagram上关注我们。
Contact MannKind:
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
Corporate Communications
(818) 292-3500
Email: media@mnkd.com
联系曼恩凯德:
投资者关系
(818) 661-5000
电子邮件：ir@mnkd.com
企业通讯
（818）292-3500
电子邮件：ir@mnkd.com
Source: MannKind
来源：曼恩凯德生物医疗